Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company provides insights and advances science to improve health and lives through unparalleled diagnostics and drug development laboratory capabilities. On January 21, 2026 company officials announced that Labcorp had been named to the Fortune World's Most Admired Companies 2026 List, a distinction recognizing the most respected and reputable companies across the globe. This year marks Labcorp’s seventh appearance on the list.

“We are honored to once again be recognized by Fortune as one of the World’s Most Admired Companies,” according to Adam Schechter, Chairman and CEO of Labcorp. “We are grateful for our employees who make this recognition possible with their commitment to help us improve health and improve lives around the world.”

The World’s Most Admired Companies survey is conducted annually by Fortune and Korn Ferry, a global organizational consulting firm. Executives, directors, and financial analysts rate companies within their industries across nine criteria, including quality of management and products, social responsibility, investment value, and ability to attract talent. A company’s score must rank in the top half of its industry survey to be listed.”

In other news, executives announced on January 28 that Labcorp is the first U.S. commercial laboratory with an agreement to implement the cobas Mass Spec solution from fellow Hacienda tenant Roche. This collaboration introduces fully automated mass spectrometry into routine clinical practice, accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide. “Labcorp is committed to advancing diagnostic science through transformative technologies,” according to Marcia Eisenberg, Ph.D., Labcorp’s Chief Scientific Officer. “Integrating Roche’s automated mass spectrometry solution will enable us to deliver greater accuracy and efficiency for critical tests that guide treatment decisions and improve patient outcomes.”

Mass spectrometry is a powerful technique for identifying and measuring molecules based on their weight and electrical charge. Its selectivity, sensitivity and accuracy make it essential for complex tests such as steroid hormone analysis, vitamin D measurement, and therapeutic drug monitoring–where even small variations can impact treatment decisions. Historically, mass spectrometry required specialized expertise and manual processes, limiting its use in routine clinical labs. Roche’s cobas Mass Spec solution changes that by automating the entire workflow–from sample preparation to result interpretation–making these critical tests faster, more reliable, and more widely accessible.”

“This collaboration reflects our shared vision to make advanced diagnostics widely accessible,” according to Brad Moore, President and CEO, Roche Diagnostics North America. “Together, we are setting a new benchmark for accuracy, reliability and efficiency in patient care.” Lapcorp became a Hacienda tenant in August 2016. The company's nearly 70,000 employees serve clients in approximately 100 countries. They provide support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world.”

For more information about Lapcorp, please visit www.labcorp.com, www.linkedin.com/company/labcorp, or https://www.facebook.com/Labcorp.